Satsuma Pharmaceuticals Web hosting Essential Viewpoint Leader Webinar on the Acute Treatment method of Migraine, DHE, and STS101

Satsuma Prescribed drugs

Thursday, June 16th @ 10:30 a.m. ET

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (World NEWSWIRE) — Satsuma Prescription drugs, Inc. (Nasdaq: STSA), a scientific-stage biopharmaceutical firm establishing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic products candidate for the acute therapy of migraine, currently announced that it will host a Important Opinion Chief (KOL) webinar on the acute treatment of migraine, DHE, and STS101 on Thursday, June 16, 2022 at 10:30 a.m. ET.

The webinar will element presentations from KOLs Amaal J. Starling, M.D., from the Mayo Clinic College of Medication and Science, and Stewart J. Tepper, M.D., from the Geisel Faculty of Drugs at Dartmouth College, who will explore the current treatment landscape and unmet health-related need to have in treating individuals suffering from migraines.

Satsuma’s STS101, dihydroergotamine nasal powder, will be reviewed as a novel investigational therapeutic product prospect for the acute procedure of migraine. John Kollins, Satsuma’s President & CEO, will provide a business update.

A live query and reply session will abide by the showcased displays by Vital Viewpoint Leaders. To RSVP for the KOL webinar, make sure you register forward of time by clicking listed here.
A replay will be offered in the Occasions & Presentations part of the Satsuma web page.        

Amaal J. Starling, M.D. is an Affiliate Professor of Neurology in the Mayo Clinic School of Medication and Science. She joined Mayo in 2012 and is at present a board-accredited Specialist within the Division of Neurology. She is presently the Medical Apply Chair of the Division of Headache the Associate Method Director for the Headache Medication Fellowship and is Software Director for the Transitional Calendar year Residency Plan in the Mayo Clinic School of Medicine and Science – Arizona Campus.

Dr. Starling received her M.D. degree from Drexel University College or university of Medicine in Philadelphia. She accomplished a Transitional Year Residency, a Neurology Residency, and a Headache Fellowship at the Mayo Clinic Faculty of Medication in Scottsdale, Arizona.

She is a Fellow of the American Academy of Neurology and the American Headache Society. She is an lively member American Clinical Association and the American Agony Culture. Dr. Starling serves on the advisory boards of the Intercontinental Concussion Modern society (ICS), NeurologyLive, the NDPH Research Foundation, the United Council for Neurologic Subspecialties, Alliance for Headache Disorders Advocacy, and the American Headache Culture. In addition, she has served as the Co-Chair of the American Headache and Migraine Affiliation, Chair of the New Investigator and Trainee Unique Desire Section and Digital Media Committee of the AHS. She is the current Advocacy Committee Chair of the AHS. She has been an invited speaker to a lot of global, countrywide, and regional conferences and has been a perennial speaker at the AHS Annual Meeting in Scottsdale, Arizona. Her numerous honors include things like the AHS Above and Over and above Award for Assistance, Manfred D. Muenter Award for Excellence in Medical Neurology, the American Academy of Neurology Once-a-year Assembly Residency Scholarship, the 2012 Spirit of Mayo Clinic Award, and the Mayo Brothers Distinguished Fellowship Award.

Dr. Starling has many peer-reviewed publications and abstracts connected to her fields of desire which involve migraine, concussion, posttraumatic headache, trigeminal autonomic cephalalgias, secondary problems, telemedicine and teleconcussion, and resident education. She is an energetic participant and member of several instructional and departmental committees inside Mayo Clinic.

Stewart J. Tepper, M.D., is Professor of Neurology at the Geisel Faculty of Drugs at Dartmouth in Hanover, New Hampshire. He is Director of the Dartmouth Headache Heart in the Section of Neurology of Dartmouth-Hitchcock Medical Heart, Lebanon, New Hampshire. Dr. Tepper received his undergraduate degree cum laude in the examine of the nervous process/psychobiology from Yale Faculty, New Haven, Connecticut, and attended Cornell University Clinical College in New York Town. He finished his Neurology residency at the Harvard Longwood Region plan, Boston, Massachusetts, and has been board certified in Headache Medicine since 2006.

Dr. Tepper was Director of the Scottsdale Headache Symposium CME class of the American Headache Culture from 2008 to 2020. He was Editor-in-Main of the journal Headache Currents and Associate Editor for the journal Headache from 2012-2020. He has posted a lot more than 450 peer-reviewed manuscripts, editorials, chapters, and guides on Headache Medicine. Dr. Tepper serves on the Govt Board of Directors and is the Company Liaison for the American Headache Culture. He serves on the AHS Education and learning, Displays, and Finance Committees. He also serves on the Governance Committee and Board of Directors of the American Migraine Basis.

About Satsuma Prescription drugs and STS101

Satsuma Prescribed drugs is a clinical-phase biopharmaceutical enterprise building a novel therapeutic item, STS101, for the acute therapy of migraine. STS101 is a distinctive and proprietary nasal powder formulation of the perfectly-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered through Satsuma’s proprietary nasal shipping gadget.  STS101 is made to provide major rewards compared to existing acute treatments for migraine, which includes the mix of quick and practical self-administration and other clinical rewards, that latest DHE liquid nasal spray goods and injectable dosage sorts deficiency. Satsuma’s dry powder DHE formulation has shown rapid absorption, rapid accomplishment of substantial DHE plasma concentrations which Satsuma thinks is important for early efficacy, and sustained DHE plasma concentrations above time with lower dose-to-dose variability. STS101 also now incorporates an enhanced 2nd-generation nasal shipping gadget built to supply much more consistent nasal dosing, irrespective of person administration system. DHE has extensive been proposed in posted migraine treatment method rules as a to start with-line acute cure solution for migraine and has major strengths vs . other anti-migraine remedies for many people. Even so, shortcomings of existing DHE liquid nasal spray and injectable products and solutions, like invasive and burdensome administration and/or sub-ideal medical functionality, have minimal the prevalent use of DHE. That includes an quick-to-have and effortless-to-use dosage type, STS101 is created to triumph over these shortcomings and supply people an improved therapeutic alternative for acutely managing migraines that continuously delivers strong medical efficiency.

Satsuma is headquartered in South San Francisco, California with functions in both California and Research Triangle Park, North Carolina. For further data, you should take a look at www.satsumarx.com.

Trader AND Company CONTACTS:

Corey Davis, PhD
LifeSci Advisors, LLC
[email protected]

Tom O’Neil, Main Monetary Officer
Satsuma Prescribed drugs, Inc.
[email protected]